New Delhi: Biophore India Pharmaceuticals on Friday said it has applied to the Drugs Controller General of India (DCGI) for obtaining emergency-use approval for Aviptadil, used in the treatment of moderate to severe cases of COVID-19.
The Hyderabad-based firm said it has developed the product which is backward integrated with its in-house API (Active Pharmaceutical Ingredient).
The company plans to commence commercial production of the product immediately after the approval is received, it added.
Aviptadil is a synthetic form of Vasoactive Intestinal Peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection.
These observations are based on results of multiple trials of Aviptadil against COVID-19 globally in patients with respiratory failure and the same have been submitted to DCGI for their review.
“The company has developed this highly complex peptide in a very short period of time, primarily due to the…
